Purpose: (a) To investigate the accuracy of cone-beam computed tomography (CBCT)-derived dose distributions relative to fanbeam-based simulation CT-derived dose distributions; and (b) to study the feasibility of CBCT dosimetry for guiding the appropriateness of replanning.
| INTRODUCTION
The need for adaptive radiotherapy has been demonstrated by many investigators. [1] [2] [3] New plans are adapted throughout the weeks-long course of fractionated radiotherapy to account for patient geometry changes resulting from weight loss, organ deformation, tumor shrinkage, and other causes. New adaptive plans may also be needed if the immobilization device needs to be adjusted or remade for variety of reasons. For some patients receiving intensity-modulated radiotherapy (IMRT) or volumetric-modulated arc therapy (VMAT), the significant benefit of replanning has been demonstrated. 4 The frequency of replanning in patients with head and neck cancer was reported to be 32%-70%, depending on criteria. 5 It is challenging, however, to decide on the appropriate time for replanning. Several investigators have looked for indicators to predict substantial dosimetric change. Although correlations between several parameters (such as weight loss, skin separation, and others) and dose change to target or organ at risk (OAR) were observed, [4] [5] [6] no single parameter can be reliably used to decide the time of replanning for patients with head and neck cancer. 4 Therefore, decisions on replanning are frequently based on the practical experience of clinicians.
The main challenge in initiating the replanning process is a lack of tools for estimation of dosimetric changes for targets and OARs.
Onboard kV cone-beam CT (CBCT) is now widely available, and CBCT-based dose calculation makes it possible to evaluate dosimetric change during the course of treatment. Although kV CBCT technology is mainly used to set up patients and localize anatomy, its potential for use in dose calculation has been recognized and reported. [7] [8] [9] [10] Dose calculation accuracy using CBCT images has been evaluated by investigators. 8, 9, [11] [12] [13] The main source of dosimetric error stemming from CBCT-based dose calculations (relative to fan-beam-based CT simulation) comes from the uncertainty in Hounsfield unit (HU)-toelectron density conversion of CBCT images. As a more direct approach, phantom-based calibration of the HU-to-electron density curve was investigated. [7] [8] [9] 13 Unlike fan-beam CT, kV CBCT suffers from scatter, which results in greater HU uncertainty. 13 
2.B | Patient-specific stepwise HU-to-density curve
Unlike the CT-based planning that uses only a single CT-to-electron density calibration curve in the treatment planning system, a patient-specific stepwise HU-to-density curve was created for each ). The treatment planning system is RayStation V5.0 (RaySearch Laboratories; Stockholm, Sweden), which provides the tool to adjust the HU threshold for each material via best match with the known material type (Fig. 1) . The HU threshold was adjusted for each patient. The optimal thresholds were attained by identifying the range of HUs for each material category based on the CBCT. The corresponding mass densities were used in dose calculation.
2.C | CBCT-based dose calculation accuracy
For each patient, CBCT scans were transferred to the RayStation treatment planning system and then registered to the planning CT based on the bony anatomy. Contours, such as planning target volume (PTV) and OARs, were copied from the planning CT to the CBCT image via rigid registration. The dose was recalculated using the original dose calculation algorithm, but using the CBCT image for both IMRT and VMAT plans. The dose calculated based on
CBCT was compared to that based on planning CT (Fig. 2) . Differences between the two plans were documented for the following dose-volume variables: dose received by 98% of the PTV (D98%, near-minimum dose), PTV D95%, PTV D2% (near-maximum dose), PTV mean dose, and PTV volume receiving ≥95% of prescription dose (V95%). Gamma analysis was performed using a criterion of 3%/3 mm for three dose zones: the zone receiving ≥90% of maximum dose (high-dose region), the zone receiving 70%-90% of maximum dose (medium-dose region), and the zone receiving 20%-70%
of maximum dose (low-dose region). These three zones represented three types of regions of interest: PTV, OARs adjacent to PTV, and OARs/normal tissue at some distance from the PTV and receiving low dose.
2.D | Comparison between CT and CBCT-based replanned dosimetry
Retrospective data from 12 additional patients with head and neck cancer were selected for evaluation of the method. These 12 patients were not included in the original cohort of 40 patients described above. Because of weight loss and source-to-skin dose changes, these patients had been rescanned based on clinicians' judgments and evaluated based on the new CT results. CBCT images acquired within 3 days of the rescanned CT images were available for these patients. The original IMRT/VMAT plans were calculated based on the rescanned CT and CBCT images. As a result of weight loss, the largest change among the investigated variables was PTV D2% (near-maximum dose). The other variables listed above had small but better changes, i.e., the PTV coverage was better, so only changes in PTV D2% between original plans and rescanned CT/ CBCT images were compared. The Pearson linear correlation coefficient was calculated.
| RESULTS

3.A | CBCT-based dose calculation accuracy
Dose differences between planning CT-based plans and CBCT-based plans for PTV are summarized in Table 1 . Gamma analysis results are shown in Table 2 . CBCT-based dose calculation accuracy does not correlate with the planning technique (VMAT vs IMRT). No difference was observed between VMAT and IMRT plans for any disease sites. Results for all disease sites are summarized in Tables 1 and 2 .
3.B | Feasibility for evaluating dosimetry
The International Commission on Radiation Units & Measurements (ICRU) Report 83 22 recommends that 85% of target points should meet the criteria of absorbed dose difference within 5% if points are
Example showing mass density on CBCT images (left) and HU thresholds to define material type (right). Mass density was assigned to each voxel via mapping CBCT HUs to six classes of materials (patient-specific HU-to-density table; right). HU threshold to define different materials can be adjusted via best match with known tissue on CBCT. Black = air; pink = adipose; light blue = tissue; gold = cartilage/bone (lung and other material not shown).
located at low-gradient areas (dose change <20%/cm) or that distance-to-agreement should be within 5 mm if points are located at high-gradient areas (dose change >20%/cm). CBCT-based dose accuracy was determined to be above the ICRU recommendation; therefore, the PTV dose-volume parameters (mean dose, D2%, D95%, D98%, and V95%) were used to decide the replanning time.
Gamma analysis using the criterion of 3%/3 mm can serve the same purpose. D2% based on CBCT predicts the change based on rescanned CT, which was assumed to be ground truth. If 3% of the change in D2%, clinical implementation has remained challenging because of the complexity of the technique or inability to achieve the accuracy required by treatment planning. In this study, we assessed the accuracy of the CBCT-based dose calculations using patient-specific stepwise HU-to-density curves and investigated the feasibility of using this method to determine replanning time. Six types of materials were used to convert the HU to density. A similar method (manually "overriding" density of all structures of interest on CBCT images) was investigated by Fotina et al., 12 who documented this as an attractive approach. Both their and our studies included pelvis patients and HN patients treated with IMRT. For their study, the dose or coverage differences (D2%, D98%, and V95%) between planning CT and CBCT were À3.2% AE 3.4%, 0.6% AE 1.8%, and 0.9% AE 2.9% for pelvis patients, and À2.3% AE 7.5%, 0.9% AE 7.1%, and À1.9% AE 1.4% for HN patients. Our method shows a slightly better dose accuracy: the dose or coverage differences (D2%, D98%, and V95%) between planning CT and CBCT were À0.4% AE 1.3%, 0.4% AE 1.1%, and 0.6% AE 0.9% for pelvis patients, and À0.5% AE 0.6%, 0.4% AE 0.7%, and 0.4% AE 0.4% for HN patients.
Because most of treatment planning systems provide the function of density overriding, our method can be easily implemented in clinical practice. The CBCT dose was compared to the dose in the initial plan, which was assumed to be ground truth. Both delivery modalities (VMAT and IMRT) were compared, and we conclude that the accuracy of CBCT-based dose calculation is not dependent on delivery technique. Four treatment sites (head and neck, lung, pancreas, and pelvis) were included in this study, and the accuracy of CBCTbased dose calculation was slightly related to the treatment sites.
Both dose statistics and gamma analysis showed that an accuracy of 3% is achievable for CBCT-based dose calculations. The gamma analysis was performed for three dose zones representing PTV, OARs receiving high dose, and OARs receiving low dose. 
4.C | Limitation of the study
Although 40 patients were selected to minimize geometric differences between planning CT and CBCT, small differences may still exist. The dosimetry difference between the CBCT plan and planning CT mainly results from the patient-specific stepwise HU-to-density F I G . 3. Change in PTV D2% relative to the prescription dose based on CBCT vs change based on CT2 for 12 patients with head and neck cancer who were rescanned because of weight loss.
curve, but geometric change, leading to dosimetric differences, cannot be excluded. However, without geometric change, dosimetric agreement between the two dose calculations would be expected to improve in this study.
This work investigates the feasibility of performing accurate dose calculations on CBCT images. We consider this calculation a necessary step toward implementing adaptive planning in our clinic. We do not address differences in anatomy observed between planning CT and CBCT as this involves clinical decision making. Actual implementation of CBCT-based replanning into the routine clinical workflow is beyond the scope of this paper.
| CONCLUSIONS
CBCT-based dose calculations produced accuracy comparable to that of simulation CT. CBCT-based dosimetry can guide the decision to replan during the course of treatment.
